Genomics

News

 

25th June 2020: practical training for optical DNA mapping after lockdown. Bionano activity can start!

equipe bionano

 

 

 

 

 

 

 

19th January 2020: set-up of the first Saphyr system and computing servers

saphyr bionano

 

 

 

 

 

 

 

In December 2019 : the Genomics Platform acquired the cutting-edge Bionano Saphyr system with the support of the Ile-de-France region (Sésame 2019), Institut Curie and the CNRS (ATIP-Avenir, Dr Chunlong Chen). This new technology uses optical DNA analysis to map the structure of each genome studied down to the allelic level and to highlight simple or complex genomic rearrangements both large and small. This instrument/technology thus allows us to keep the platform’s genomic analysis capabilities at the cutting edge, in addition to analyses performed by high-throughput sequencing, CGH / SNParray, or cytogenetics The Bionano approach will be used for basic research (DNA replication, immune system, etc.) and applied to the understanding of various pathologies: cancer, rare diseases, and neurodegenerative pathologies in virology. We hope to be able to extend the applications of this new technology by customizing it, for example, by targeting DNA sequences of with the support of local or external partners (public laboratories and platforms, small businesses).

https://bionanogenomics.com/

Analytical workflow/Workflow of the Bionano process:

processus bionana

 

 

 

 

 

 

Illustration of detectable structural alterations:

analyses bionano

 

 

 

 

 

 

 

 


A collaboration between Institut Curie and Prédilife began in spring 2019 to carry out genetic analyses of the MammoRisk predictive test using saliva samples. This collaboration has enabled the platform to implement several systems: a high-throughput nucleic acid extraction robot (KingFisher), a spotter robot for Open Arrays support (Accufill), and a real-time PCR device (QuantStudio 12Flex).

https://www.thermofisher.com/fr/fr/home/life-science/pcr/real-time-pcr/real-time-openarray.html?SID=fr-openarray-main

predilife

 

 

 

 

 

 

The high-throughput genotyping activity was set up in conjunction with Dr Lisa Golmard and Prof Dominique Stoppa-Lyonnet from the Institut Curie Hospital Group Genetics Department. This study will facilitates the establishment of clinical reports using the Polygenic Risk Score (PRS) developed by Prédilife.

https://www.predilife.com/home.php

 

MammoRisk around

MammoRisk CR

 


Since spring 2018, setup of high throughput genotyping analysis, based on Thermofisher microarrays: APMRA (Axiom Precision Medecine Research Arrays).          http://thermofisher.com/pmra

Axiom_1

 

 

 

 

 

 

 

 


Since summer 2017, setup of Nanostring 3D biology technics to measure DNA, RNA and proteins on Fresh Frozen material and Formalin Fixed Paraffin Embedded samples (FFPE).

https://www.nanostring.com/scientific-content/technology-overview/3d-biology-technology

nanostring 3D

 

 

 

 

 


Since March 2017, the Genomic Platform acquired a Fragment Analyzer, which is a High throughput capillary electrophoresis device (48 well capillary).

What does this device do?  This technology allows diverse analyses that quantify and qualify, with high precision, nucleic acids. DNA/RNA molecules from frozen tissues, formalin fixed and paraffin-embedded tissues, CSF, plasma, laser microdissection preparation, ctDNA, as well as products for NGS libraries can be monitored with a large spectrum of concentrations (5 μg /μL to 500 ng/ μL depending on kits).

This equipment was financed, thanks to the support of the Canceropole Ile de France and the Institut Curie.

If you have any questions, do not hesitate to contact us at the platform or to visit this site:

https://www.aati-us.com/instruments/fragment-analyzer/

 


13th of October 13, 2016, the partnership Cambridge Epigenetix (CEGX) and the Institut Curie was renewed for one year.

This partnership led to the creation of an “Epigenome Center” for which the Genomics and NGS platforms have been trained in the processes developed by CEGX. Analysis of DNA methylation (5mC, 5hmC) is currently proposed to the scientific fellowship.

About Cambridge Epigenetix (CEGX)

why-cegx

 

 

 

 


1st of October, 2016, the Genomics Platform and Nanostring signed an agreement for the creation of a backup laboratory in Europe that can performed the Prosigna Breast Cancer Pronostic Gene Signature assay (Pam50 tests).

This agreement is based on the regular activity of the PAM50 tests carried out at the Institut Curie. It allows the update of Nanostring equipments, and doubles the Prosigna test capacities made by the Institut Curie. This accession strengthens the links between Institut Curie and Nanostring.

About Prosigna